Health care supply in patients with Ehlers-Danlos syndromes and generalized hypermobility spectrum disorder: a German perspective
- PMID: 40819036
- PMCID: PMC12358066
- DOI: 10.1186/s13023-025-03937-4
Health care supply in patients with Ehlers-Danlos syndromes and generalized hypermobility spectrum disorder: a German perspective
Abstract
Background: Diagnosing Ehlers-Danlos syndromes (EDS) and EDS-related "hypermobility spectrum disorder" (HSD) is challenging and cutaneous manifestations often serve as indicators of these rare connective tissue disorders. Only limited data exist on the healthcare of EDS/HSD in Germany as specialized services have been missing and a national register is not available.
Objectives: In 2020, a dermatologic-orthopedic EDS outpatient service was initiated at the University Hospital of Cologne, Germany. The objectives of the present survey were to examine the "medical journey" and the disease burden of our patients.
Methods: A pseudonymized paper survey was sent to all adults who were diagnosed with hypermobile EDS (hEDS), classical EDS (cEDS), classical-like EDS (clEDS) or generalized HSD at the EDS Cologne service from December 2021 until May 2023.
Results: Of the 99 participants, 80 were diagnosed with hEDS/HSD, 16 with cEDS and 3 with clEDS. The mean time to diagnosis was 22.0 years (14.5 years for cEDS/clEDS vs. 23.0 years for hEDS/HSD). 24.2% of the participants had a recognized degree of disability of ≥ 50, the average sick leave in the last 3 months was 4.6 days for cEDS/clEDS and 21.3 days for hEDS/HSD. 44.9% of the hEDS/HSD patients reported on having at least four comorbidities compared to 21.1% in the cEDS/clEDS group (p = 0.023). At least 15 medical specialties were involved in the diagnostics and treatment of participants with multiple therapeutic modalities.
Conclusions: This is the first study providing an insight on the healthcare supply of EDS/HSD patients in Germany. Participants in our survey had a much longer "diagnostic journey" than the one in previous studies and suffered from high morbidity despite high healthcare utilization. Our results point to the urgent necessity of a better coordinated, multidisciplinary care for patients with these complex genodermatoses including innovative political structures, further research and international networking.
Keywords: Burden of disease; Diagnostic odyssey; Ehlers-danlos syndromes; Generalized hypermobility; Genodermatoses; Health care supply; Hereditary connective skin disorders; Hypermobility spectrum disorder; Rare diseases.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: Reviewed and approved by the Ethics Committee of the University Hospital of Cologne, Germany (DRKS00024554). Consent for publication: The patients in this manuscript have given written informed consent to the publication of their case details. Competing interests: None declared.
Similar articles
-
AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review.Clin Gastroenterol Hepatol. 2025 Jul;23(8):1291-1302. doi: 10.1016/j.cgh.2025.02.015. Epub 2025 May 19. Clin Gastroenterol Hepatol. 2025. PMID: 40387691 Review.
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
Integrative medicine for hypermobility spectrum disorders (HSD) and Ehlers-Danlos syndromes (EDS): a feasibility study.Disabil Rehabil. 2024 Dec;46(24):5854-5867. doi: 10.1080/09638288.2024.2314713. Epub 2024 Feb 14. Disabil Rehabil. 2024. PMID: 38353245 Clinical Trial.
-
Autism in the context of joint hypermobility, hypermobility spectrum disorders, and Ehlers-Danlos syndromes: A systematic review and prevalence meta-analyses.Autism. 2025 Aug;29(8):1939-1958. doi: 10.1177/13623613251328059. Epub 2025 Mar 27. Autism. 2025. PMID: 40145613
-
Classic Ehlers-Danlos Syndrome.2007 May 29 [updated 2024 Feb 1]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2007 May 29 [updated 2024 Feb 1]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 20301422 Free Books & Documents. Review.
References
-
- Malfait F, Francomano C, Byers P, Belmont J, Berglund B, Black J, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):8–26. - PubMed
-
- Malfait F, Castori M, Francomano CA, Giunta C, Kosho T, Byers PH. The Ehlers–Danlos syndromes. Nat Rev Dis Primer. 2020;6(1):64. - PubMed
-
- Chernogubow AN. Uber einen fall von cutis Laxa. Jahresber Ges Med 27. 1892;562.
-
- Parapia LA, Jackson C. Ehlers-Danlos syndrome– a historical review. Br J Haematol. 2008;141(1):32–5. - PubMed
-
- Doolan BJ, Lavallee M, Hausser I, Pope FM, Seneviratne SL, Winship IM, et al. Dermatologic manifestations and diagnostic assessments of the Ehlers-Danlos syndromes: A clinical review. J Am Acad Dermatol. 2023;89(3):551–9. - PubMed
LinkOut - more resources
Full Text Sources